The Food and Drug Administration (FDA) sent Johnson & Johnson a letter to warn the drug maker about an online video for its chronic pain drug Ultram ER, says The Wall Street Journal.

The FDA said in the letter that the video "greatly misrepresent[ed]" the drug by suggesting that it can have a positive impact on a patient's mood, notes the Journal, and it wants the company to distribute "truthful, nonmisleading, and complete corrective messages" about Ultram ER.

Although the video was posted to www.painawareness.org, it has since been removed. The site was launched by Aventine HealthSciences, a medical communications agency, for Pain Awareness Month.